Candidate

REGENXBIO Announces Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients

– The company launched Phase I/II AFFINITY DUCHENNE™ testing RGX-202 – The company is also including a new active observational screening study, AFFINITY BEYOND, evaluating the prevalence of AAV8 antibodies in boys with Duchenne – Commercial cGMP material from REGENXBIO Manufacturing Innovation Center to be used in clinical trial – RGX-202 is a potential single-agent …

REGENXBIO Announces Phase I/II Trial of RGX-202, Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, Is Active and Recruiting Patients Read More »

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease

TORONTO, December 28, 2022—(BUSINESS WIRE)–Biomind Labs Inc. (“Biomind Labs” or “Society“) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotechnology company focused on developing the next generation of medicines to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the healing power of psychedelic molecules, is pleased to announce that successfully completed the …

Biomind Labs Announces Completion of First Sublingual Psychedelic Formulation for Its Drug Candidate BMND08 for Depression and Anxiety in Alzheimer’s Disease Read More »